|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the South Texas Veterans Health Care System, and
Department of Medicine, Division of Hematology, University of Texas
Health Science Center, San Antonio, TX; Department of Medicine,
Division of Hematology-Oncology, Duke University Medical Center,
Durham, NC; and Department of Medicine, University of Alabama at
Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham.
A drug that specifically inhibits erythropoiesis would be
clinically useful. The erythropoietin (Epo) mutant Epo (R103A) could potentially be used for this purpose. Epo (R103A) has a single amino
acid substitution of alanine for arginine at position 103. Because of
this mutation, Epo (R103A) is only able to bind to one of the 2 subunits of the erythropoietin receptor (EpoR) homodimer and is thus a
competitive inhibitor of Epo activity. To produce large quantities of
Epo (R103A) to test in animal models of thalassemia and sickle cell
disease, we expressed and purified recombinant Epo (R103A) from the
yeast Pichia pastoris. Using this method milligram
quantities of highly purified Epo (R103A) are obtained. The
yeast-expressed Epo (R103A) is properly processed and glycosylated and
specifically inhibits Epo-dependent cell growth and
125I-Epo binding. Epo (R103A) does not, however, directly
induce apoptosis in 32D cells expressing EpoR. Epo (R103A) inhibits
erythropoiesis of human CD34+ hematopoietic cells and
completely blocks erythroid burst-forming unit formation in normal
human bone marrow colony assays. Yeast-expressed Epo (R103A) is a
specific inhibitor of primary erythropoiesis suitable for testing in
animal models.
(Blood. 2002;99:4400-4405) Blood transfusion is commonly used in the treatment
hemoglobinopathies. One of the goals of blood transfusion in these
diseases is the suppression of abnormal endogenous erythropoiesis. For instance, thalassemia major is associated with ineffective
erythropoiesis and massive bone marrow expansion. This bone marrow
expansion has numerous adverse effects, including hypersplenism, bone
abnormalities, growth retardation, increased susceptibility to
infection, and endocrine abnormalities.1 Transfusion
therapy regimens can dramatically ameliorate these problems.
Patients with sickle cell disease may have a relative erythrocytosis
such that oxygen delivery begins to decrease at hematocrits as low as
30% to 35%.2 This decreased oxygen delivery is a consequence of the abnormal rheology of sickle red blood
cells.3 The resulting hyperviscosity is associated with
serious clinical conditions such as acute chest syndrome and acute
multiorgan damage syndrome.4,5 These complications require
treatment with exchange blood transfusions.
In both thalassemia and sickle cell disease chronic transfusion
therapy can have important complications including iron overload, viral
hepatitis, and alloimmunization. Drug therapy that specifically and
safely inhibits erythropoiesis would be desirable for these patients.
A potential drug for specific inhibition of erythropoiesis is the
erythropoietin (Epo) mutant Epo (R103A). Epo (R103A) has a mutation of
alanine for arginine at amino acid position 103. Epo (R103A) was
discovered during mutational studies to define important amino acid
residues required for Epo activity.6 Epo (R103A)
completely lacks the ability to support mitogenesis in cells expressing
the erythropoietin receptor (EpoR).6,7
Biochemical and crystallographic studies have shown that Epo has
nonidentical binding sites for each of the 2 identical EpoR subunits in
the preformed EpoR homodimer.8,9 Epo binding site 1 interacts with the first EpoR subunit with nanomolar
affinity.10 Epo binding site 2 interacts with the second
subunit of the EpoR homodimer with micromolar affinity.10
The resulting subnanomolar affinity of Epo for the EpoR dimer is the
consequence of the 2 binding interactions. The interaction of Epo with
the receptor homodimer results in a conformational shift of the
subunits such that cytoplasmic signal transduction is activated.
Arginine 103 of Epo is the primary residue involved in the second EpoR
binding surface.11 Mutation of arginine 103 to alanine
disrupts this binding interaction. Epo (R103A) is thus unable to induce
activation of the EpoR. Because it retains the ability to bind the
first EpoR subunit, Epo (R103A) is a competitive inhibitor of Epo
activity.12
To study the in vivo activity of Epo (R103A) in animal models of
thalassemia and sickle cell disease, we have expressed Epo (R103A) in
the yeast Pichia pastoris. This methanotropic yeast allows
high-level expression of properly glycosylated and folded recombinant
proteins.13 We describe here the purification and biochemical characterization of yeast-expressed Epo (R103A). In addition, we demonstrate the ability of Epo (R103A) to inhibit erythropoiesis of primary human hematopoietic cells.
Expression and isolation of yeast Epo antagonist
The resulting construct, Epo (R103A)/pPICZ This clone, Epo (R103A)/GS115 clone no. 4, was inoculated into
2 × 500 mL 1% yeast extract, 2% peptone, 0.1 M potassium
phosphate, pH 6.0, 1.34% yeast nitrogen base,
4 × 10 After 5 days of culture in methanol, the yeast-conditioned media were
collected by centrifugation. The 200 mL yeast-conditioned media were
concentrated to 20 mL with Centriprep 10 YM concentrators (Millipore,
Bedford, MA) and dialyzed overnight into 5 mM imidazole, 0.5 M NaCl, 20 mM Tris, pH 8.0 (binding buffer). A 1-mL solution (50% slurry) of
Ni-NTA resin (Qiagen, Valencia, CA) was washed twice with water and
then twice with binding buffer in a 50-mL conical centrifuge tube. The
dialyzed yeast-conditioned media was added to the washed Ni-NTA resin
and incubated with rocking for 4.5 hours at 4°C. The beads were
collected by centrifugation and washed twice in 10 mL 0.5 M NaCl, 20 mM
Tris, pH 8.0 (wash buffer). Enough wash buffer was then added to
produce a 50% slurry. The slurry was packed into a 4-mL plastic
chromatography column. The column was washed with wash buffer until the
absorbance at 280 nm was less than 0.01. The bound protein was eluted
with 0.25 M imidazole, 0.5 M NaCl, 20 mM Tris, pH 8.0. Fractions of 1 mL were collected. Fractions with an absorbance at 280 nm more than 0.1 were collected and pooled. The pooled fractions were dialyzed overnight
into 0.15 M NaCl, 20 mM Tris, pH 7.4. The dialyzed Epo (R103A) was
sterilized using a syringe filter and the final protein concentration
determined using the DC Protein Assay (Bio-Rad, Hercules, CA).
Wild-type human Epo was expressed and purified from P
pastoris exactly as described above for Epo (R103A).
Purified Epo (R103A) was subjected to N-glycanase digestion as
suggested by the manufacturer (New England Biolabs, Beverly, MA).
Carbohydrate stains on nitrocellulose membranes were performed with the
Glycan Detection Kit (Roche, Indianapolis, IN) as described by the manufacturer.
Cell culture
125I-Epo binding assays were performed with 125I-Epo (Amersham, Piscataway, NJ) as previously described.16 Cell growth and viability were measured using methyl-thiazol-diphenyl-tetrazolium (MTT) reagent (Sigma, St Louis, MO) or 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium (MTS) reagent (Promega, Madison, WI) as described by the manufacturers. Conversion of commercial recombinant Epo from U/mL to µg/mL was performed using the published value of 129 000 U/mg.17 Apoptosis was assessed by flow cytometry using Alexa 488-labeled annexin V (Molecular Probes, Eugene, OR) as described by the manufacturer. Primary cell cultures and proliferation and viability assays Human umbilical cord blood (UCB) was obtained from the Department of Obstetrics and Gynecology of Duke University Medical Center through an Institutional Review Board-approved protocol after normal full-term pregnancy. Peripheral blood mononuclear cells were collected from healthy volunteers. Cord blood units and cells were diluted with 50 mL phosphate-buffered saline containing 0.8% bovine serum albumin and then submitted to Ficoll density gradient separation. The mononuclear cells were harvested and enriched for CD34+ cells by positive selection using anti-CD34 antibody and magnetic cell sorting on Mini-MACS columns (CD34 isolation kit, Miltenyi Biotec, Auburn, CA). CD34+ enriched cells were cultured in growth medium containing 100 ng/mL human stem cell factor (SCF; Sigma, St Louis, MO), 7.5 ng/mL recombinant human Epo (Ortho Biotech, Raritan, NJ), 40 ng/mL insulinlike growth factor (Sigma), 10 6 M dexamethasone (Sigma), and
106 M  -estradiol (Sigma) as described
previously.18 On day 9 of culture, cells were analyzed for
surface expression of CD71 by flow cytometry to confirm the purity of
the erythroid cell population. Staining of the cells using monoclonal,
fluorescein isothiocyanate (FITC)-conjugated antihuman CD71 (Sigma)
and FITC-mouse isotype control followed by flow cytometry analysis
confirmed more than 99% CD71 positivity of the erythroid cell
population. Morphologic examination of the Wright stains of cells
cytocentrifuged onto glass slides confirmed the presence of a
homogeneous population of erythroid cells with proerythroblast
morphology. Cells were washed with serum-free culture medium and then
placed in differentiation medium containing 7.5 ng/mL Epo and 1 µg/mL
recombinant human insulin (Humulin-R, Lilly, Indianapolis, IN)
as described to induce further expansion during terminal
differentiation.18 For dose-response experiments in the
presence of Epo (R103A), 106 cells were placed in 3 mL
culture medium with various concentrations of Epo (R103A) and cells
were counted daily using a hemocytometer. Day 9 erythroblasts were
plated in 96-well plates (5000-40 000 cells/well) and maintained in
differentiation medium with various concentrations of added Epo
(R103A). At 5 days, medium was aspirated from the wells and MTT reagent
(1 mg/mL) was added to each well. The cells were then incubated for 1 hour in 37°C, lysed with isopropanol and read in an enzyme-linked
immunosorbent assay (ELISA) plate reader at 570 to 650 nm. Assays were
performed in triplicate. Results were analyzed for statistical
significance using the Student t test.
Bone marrow colony assays were performed using bone marrow aspirates from healthy volunteers via a protocol approved by the University of Alabama at Birmingham Institutional Review Board. Bone marrow mononuclear cells (1 × 105/mL) were plated in Methocult complete methylcellulose media (Stem Cell Technologies, Vancouver, BC) containing SCF (50 ng/mL), granulocyte-macrophage colony-stimulating factor (GM-CSF; 10 ng/mL), and IL-3 (10 ng/mL). Some cultures also contained Epo (23 ng/mL) or Epo (R103A) or both as indicated. Cultures were maintained for 14 days in 5% CO2 at 37°C and then all colonies on the plate were counted.
Recombinant Epo (R103A) protein was expressed and purified from
the yeast P pastoris. The human Epo (R103A) cDNA sequence (including C-terminal polyhistidine tag) was subcloned into the yeast
expression vector pPICZ
The purified yeast-expressed Epo (R103A) was biochemically
characterized. To demonstrate proper processing by the yeast secretory pathway, the N-terminal sequence of the purified protein was determined (Figure 1C). The sequence demonstrates proper cleavage of the The degree of glycosylation of Epo (R103A) was determined using
N-glycanase digestion (Figure 2). The Epo
(R103A) peptide has a predicted molecular weight of 21 000.
The 32 000 molecular weight purified Epo (R103A) is reduced to 22 000
molecular weight following digestion with N-glycanase. This is
consistent with 10 000 molecular weight of N-linked glycosylation. A
small amount of carbohydrate staining remains following N-glycanase
digestion, consistent with 1000 molecular weight of residual O-linked
sugars (Figure 2, open arrow). The yeast-expressed Epo (R103A) thus has amounts of N- and O-linked glycosylation similar to mammalian-expressed Epo.20
As previously reported for mammalian-expressed Epo
(R103A),12 yeast-expressed Epo (R103A) is a potent
antagonist of Epo growth (Figure 3A).
Addition of Epo (R103A) caused a dose-dependent inhibition of growth of
32D cells expressing the full- length human EpoR (32D/EpoR WT cells)
with half-maximal inhibition at approximately 0.5 µg/mL (equivalent
to 15.6 nM). At 1 µg/mL Epo (R103A) added (approximately 80-fold
excess with regard to the Epo concentration used) there was a complete
absence of cell growth. Trypan blue staining revealed that all cells
incubated for 3 days in 1 µg/mL Epo (R103A) were nonviable (data not
shown). Epo (R103A) had no effect on IL-3-dependent growth of these
cells (open squares). Similar results were seen with 32D cells
expressing the murine EpoR and with BaF3 cells expressing the human
EpoR (data not shown).
We have previously shown that 32D cells expressing a cytoplasmically truncated EpoR associated with the disease familial erythrocytosis (FE) are hypersensitive to Epo-induced growth.15,21 As shown in Figure 3B, Epo (R103A) also effectively blocked Epo-induced growth of 32D expressing the EpoR FE (32D/EpoR FE cells). In our hands, the inhibition of EpoR FE routinely requires about 5-fold more Epo (R103A) compared to inhibition of wild-type EpoR (compare inhibition of viability at 1 µg/mL in Figure 3). This right-shift of the inhibition curve is likely a reflection of the hypersensitivity of the truncated EpoR for Epo (eg, it takes more complete blockade of the EpoR FE to obtain equivalent biologic effect). Epo (R103A) is a competitive inhibitor of 125I-Epo binding
(Figure 4). The apparent Ki
was 10 nM (approximately 0.32 µg/mL) under the conditions of this
experiment. This is similar to the half-maximal inhibition by Epo
(R103A) of Epo-induced growth (0.5 µg/mL) described above. At
concentrations above 1000 nM, only nonspecific binding of
125I-Epo occurred (compare binding in the presence of
excess unlabeled Epo, closed circle).
A GM-CSF mutant with structural and antagonistic properties similar to
Epo (R103A) has been reported to directly activate apoptosis in myeloid
precursor cells.22 We tested if Epo (R103A) is able to
directly activate apoptosis. 32D/EpoR cells were treated with 10% WEHI
(as a source of IL-3), Epo, or Epo (R103A) for 24 hours. The cells were
harvested and apoptosis was determined by measuring annexin V binding
(Figure 5). In this rapidly growing cell
line, about 20% of cells are undergoing apoptosis at steady state
under normal growth conditions (10% WEHI, Epo, or Epo plus 10% WEHI).
In contrast, about 50% of cells cultured in Epo (R103A) are undergoing
apoptosis (dotted bar). This is similar to the degree of
apoptosis in the absence of any cytokine (black bar). Thus, Epo (R103A)
is unable to support antiapoptotic pathways. However, addition of 10%
WEHI to cells cultured in Epo (R103A) (hatched bar) returns the degree
of apoptosis to the background level. Thus, Epo (R103A) does not
directly induce apoptosis in this system.
Epo (R103A) effectively inhibits erythropoiesis of primary human
hematopoietic cells (Figure 6). UCB
CD34+ cells were used in an in vitro erythropoiesis culture
system to obtain normal proerythroblasts.18
Proerythroblasts were incubated for 5 days in the presence of
increasing concentrations of Epo (R103A). There was a dose-dependent
inhibition of the ability of Epo to support expansion of these
proerythroblasts (Figure 6A). This inhibition of proerythroblast
expansion was associated with a dose-dependent inhibition of cellular
viability by Epo (R103A) (Figure 6B).
Epo (R103A) is also a specific inhibitor of day 14 erythroid
burst-forming units (BFU-Es) in human bone marrow cultures (Figure 7). In the presence of Epo and 1 µg/mL
Epo (R103A), the number of BFU-Es was decreased to about 33% of the
number in Epo alone (Figure 7A). In the presence of Epo and 10 µg/mL
Epo (R103A) (a concentration sufficient to completely saturate the
EpoR, Figure 4), BFU-E formation was completely blocked (Figure 7B).
There was no effect on nonerythroid colony number (GM-CFU) with Epo (R103A) treatment. Epo (R103A) alone was unable to support BFU-E viability and differentiation.
The present work was undertaken with the long-range goal of determining if Epo (R103A) may have useful activity as a drug for the suppression of erythropoiesis. Previous studies of Epo (R103A) have used unpurified conditioned media from transfected mammalian cells6,7,12 or polyhistidine tagged Epo (R103A) purified from mammalian cell conditioned media.23 Levels of secreted Epo (R103A) obtained in these studies ranged from 0.01 to 1 µg/mL. In the only study in which Epo (R103A) was purified, the final yield was not described and the purity of the isolated protein was not demonstrated.23 These previously reported preparations of Epo (R103A) are thus not sufficiently characterized for animal studies. Because Epo (R103A) binds with a 50-fold lower affinity to the EpoR compared to wild-type Epo (10 nM compared to 200 pM for Epo), large quantities of Epo (R103A) will be required for in vivo use. To obtain the large quantities of purified protein required for animal studies, we elected to express and purify Epo (R103A) from the yeast P pastoris. Using this method we can easily and inexpensively obtain up to 12 mg purified Epo (R103A) using 6 L yeast culture. Yields of 10-fold higher or more are possible with fermentation methods. We have biochemically characterized the yeast-expressed Epo (R103A) with respect to N-terminal sequence, glycosylation, and receptor-binding activity. N-terminal sequence and glycosylation were found to be similar to wild-type, mammalian cell-expressed Epo. Appropriate glycosylation is of particular importance to ensure adequate pharmacokinetics in vivo, because unglycosylated Epo has a first-pass clearance in the liver.17 We demonstrate that Epo (R103A) will antagonize 125I-Epo binding to the EpoR. The inhibition of 125I-Epo binding by Epo (R103A) has not previously been demonstrated. The agreement between the apparent Ki for inhibition of 125I-Epo binding and the half-maximal inhibition of cell growth (Figures 3 and 4) is consistent with a mechanism of growth inhibition by Epo (R103A) based on competitive binding to the EpoR. We have also characterized the biologic activity of the yeast-expressed Epo (R103A). We have confirmed previous work in which Epo (R103A) was shown to be an antagonist for Epo-dependent growth of cultured cell lines.12 In addition, we show that Epo (R103A) effectively and specifically antagonizes erythropoiesis of primary human erythroid cells from bone marrow and UCB (Figures 6 and 7). This inhibition of erythropoiesis is due, at least in part, to decreased viability of the cells in presence of Epo (R103A). This decreased viability is likely due to the fact that erythroid precursors have an absolute requirement for Epo to avoid apoptosis24 rather than by direct activation of apoptosis by Epo (R103A) (Figure 5). The dose-dependent inhibition of in vitro erythropoiesis is about 10-fold higher than that for direct competition for 125I-Epo binding. As shown in Figure 4, the apparent Ki for inhibition of 125I-Epo binding is 0.32 µg/mL (equivalent to 10 nM), whereas half-maximal inhibition of in vitro erythropoiesis occurs at about 5 µg/mL (Figure 6). This difference might represent the residual biologic activity of the very few EpoR occupied by Epo in the presence of 5 µg/mL Epo (R103A). Epo (R103A) exhibits an inhibitory effect on in vitro erythropoiesis over a wide range of concentrations from 0.1 to 10 µg/mL (Figure 6B). The dose-dependent inhibition of viability was significant over all doses of Epo (R103A) tested. This suggests that Epo (R103A) could be effectively used in vivo to titrate erythropoietic activity. Yeast-expressed Epo (R103A) thus represents a high-yield, low-cost, and well-characterized reagent that is suitable for studies in animal models. Epo (R103A) has several potential research and clinical uses. As a research reagent, Epo (R103A) could be useful in the study of the regulation of erythropoiesis in vivo in animals, as well as in the study of nonerythropoietic functions of Epo, such as on endothelium.25,26 Epo (R103A) could be useful in suppressing endogenous abnormal erythropoiesis in diseases such as sickle cell anemia and thalassemia major. Yeast-expressed Epo (R103A) has the potential to be immunogenic, due both to the amino acid point mutation and the yeast glycosylation. This potential immunogenicity will need to be evaluated in animal models. We do not anticipate that Epo (R103A) will be an alternative to phlebotomy for most patients with erythrocytosis because phlebotomy is inexpensive, easy, and safe to perform, and is free of substantial side effects. Several other mutant cytokines with antagonist properties have been described, including antagonists of growth hormone,27 GM-CSF,22 IL-6,28 and IL-13.29 The marked specificity of these agents makes them attractive potential drugs. The availability of large quantities of characterized yeast expressed Epo (R103A) will allow further studies to determine if this agent will have clinical utility as member of this new class of drugs.
We thank Dr Frank Bunn for the kind gift of Epo (R103A). Epo was a kind gift of Ortho Biotech, Raritan, NJ. Dr Linda Bonewald performed the protein sequencing at the University of Texas Health Science Center at San Antonio Protein Core Facility. Flow cytometry was performed at the University of Alabama at Birmingham Arthritis Center flow cytometry core. Vijaya Sambandam and Latania Watson provided excellent technical assistance.
Submitted July 13, 2001; accepted January 23, 2002.
Supported by a Veterans Administration Merit Review grant (K.W.H.) and National Institutes of Health grant DK-02566 (M.O.A.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Kevin W. Harris, Division of Hematology/Oncology, University of Alabama at Birmingham, Wallace Tumor Institute 520-D, 1530 3rd Ave S, Birmingham, AL 35294; e-mail: kevin.harris{at}ccc.uab.edu.
1. Forget BG. Thalassemia syndromes. In: Hoffman R,Shattil SJ,Furie B,Cohen HJ,Silberstein L,McGlave P, eds. Hematology Basic Principles and Practice. New York, NY: Churchill Livingston; 2000:485-510. 2. Schmalzer EA, Lee JO, Brown AK, Usami S, Chien S. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion. 1987;27:228-233[CrossRef][Medline] [Order article via Infotrieve]. 3. Chien S, Usami S, Bertles JF. Abnormal rheology of oxygenated blood in sickle cell anemia. J Clin Invest. 1970;49:623-634[Medline] [Order article via Infotrieve].
4.
Castro O, Brambilla DJ, Thorington B, et al.
The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.
Blood.
1994;84:643-649 5. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med. 1994;96:155-162[CrossRef][Medline] [Order article via Infotrieve]. 6. Grodberg J, Davis KL, Sykowski AJ. Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Eur J Biochem. 1993;218:597-601[Medline] [Order article via Infotrieve].
7.
Wen D, Boissel JP, Showers M, Ruch BC, Bunn HF.
Erythropoietin structure-function relationships. Identification of functionally important domains.
J Biol Chem.
1994;269:22839-22846
8.
Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA.
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.
Science.
1999;283:987-990
9.
Remy I, Wilson IA, Michnick SW.
Erythropoietin receptor activation by a ligand-induced conformation change.
Science.
1999;283:990-993 10. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry. 1996;35:1681-1691[CrossRef][Medline] [Order article via Infotrieve]. 11. Syed RS, Reid SW, Li C, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395:511-516[CrossRef][Medline] [Order article via Infotrieve].
12.
Matthews DJ, Topping RS, Cass RT, Giebel LB.
A sequential dimerization mechanism for erythropoietin receptor activation.
Proc Natl Acad Sci U S A.
1996;93:9471-9476 13. Cregg JM, Vedvick TS, Raschke WC. Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology. 1993;11:905-910[CrossRef][Medline] [Order article via Infotrieve].
14.
Boissel JP, Lee WR, Presnell SR, Cohen FE, Bunn HF.
Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure.
J Biol Chem.
1993;268:15983-15993
15.
Arcasoy MO, Degar BA, Harris KW, Forget BG.
Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.
Blood.
1997;89:4628-4635
16.
Harris KW, Mitchell RA, Winkelmann JC.
Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in Escherichia coli.
J Biol Chem.
1992;267:15205-15209
17.
Krantz SB.
Erythropoietin.
Blood.
1991;77:419-434
18.
Panzenbock B, Bartunek P, Mapara MY, Zenke M.
Growth and differentiation of human stem cell factor/erythropoietin- dependent erythroid progenitor cells in vitro.
Blood.
1998;92:3658-3668
19.
Brake AJ, Merryweather JP, Coit DG, et al.
Alpha-factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae.
Proc Natl Acad Sci U S A.
1984;81:4642-4646 20. Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 1986;172:213-224[Medline] [Order article via Infotrieve]. 21. Arcasoy MO, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol. 1999;27:63-74[CrossRef][Medline] [Order article via Infotrieve].
22.
Iversen PO, To LB, Lopez AF.
Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R.
Proc Natl Acad Sci U S A.
1996;93:2785-2789
23.
Qiu H, Belanger A, Yoon H-WP, Bunn HF.
Homodimerization restores biological activity to an inactive erythropoietin mutant.
J Biol Chem.
1998;273:11173-11176
24.
Koury M, Bondurant M.
Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells.
Science.
1990;248:378-381 25. Noguchi K, Yamashiro S, Matsuzaki T, Sakanashi M, Nakasone J, Miyagi K. Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits. Br J Pharmacol. 2001;133:395-405[CrossRef][Medline] [Order article via Infotrieve].
26.
Ribatti D, Presta M, Vacca A, et al.
Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.
Blood.
1999;93:2627-2636
27.
Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA.
Rational design of potent antagonists to the human growth hormone receptor.
Science.
1992;256:1677-1680 28. Toniatti C, Cabibbo A, Sporena E, et al. Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO J. 1996;15:2726-2737[Medline] [Order article via Infotrieve].
29.
Oshima Y, Puri RK.
Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13.
J Biol Chem.
2001;276:15185-15191
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
Top
Abstract
Introduction
(Invitrogen, Carlsbad, CA). This vector
allows insertion of the Epo (R103A) sequence into the alcohol oxygenase
locus of the methanotropic yeast P pastoris. Expression of
Epo (R103A) can thus be induced by growth in methanol. This vector
includes a C-terminal polyhistidine tag (for purification of
recombinant fusion protein on Ni2+ agarose beads) and a myc
tag. Addition of a polyhistidine tag to the C-terminus does not effect
the biologic activity of Epo.
. The left gel shows glycosylation
detected using glycan stain. The open arrow indicates residual glycan
staining due to O-linked glycosylation. The right gel shows a Western
blot using anti-Epo antibody. The blot was overloaded to demonstrate
complete digestion.
